130 related articles for article (PubMed ID: 38373667)
1. Clinical value of molecular subtypes identification based on anoikis-related lncRNAs in castration-resistant prostate cancer.
Chen K; Zhang Y; Li C; Liu Y; Cao Q; Zhang X
Cell Signal; 2024 May; 117():111104. PubMed ID: 38373667
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy.
Zhang YY; Li XW; Li XD; Zhou TT; Chen C; Liu JW; Wang L; Jiang X; Wang L; Liu M; Zhao YG; Li SD
Front Immunol; 2022; 13():1055304. PubMed ID: 36505486
[TBL] [Abstract][Full Text] [Related]
3. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of anoikis-related lncRNAs for prognostic significance and immune microenvironment characterization in ovarian cancer.
Cao L; Zhang S; Peng H; Lin Y; Xi Z; Lin W; Guo J; Wu G; Yu F; Zhang H; Ye H
Aging (Albany NY); 2024 Jan; 16(2):1463-1483. PubMed ID: 38226979
[TBL] [Abstract][Full Text] [Related]
5. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
6. Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer.
Zhang Q; Zhang P; Zhao Z; Wang J; Zhang H
PeerJ; 2023; 11():e15013. PubMed ID: 37070095
[TBL] [Abstract][Full Text] [Related]
7. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
8. Construction of stomach adenocarcinoma prognostic signature based on anoikis-related lncRNAs and clinical significance.
Lu L; Yu M; Huang W; Chen H; Jiang G; Li G
Libyan J Med; 2023 Dec; 18(1):2220153. PubMed ID: 37300839
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma.
Wu B; Zhang X; Feng N; Guo Z; Gao L; Wan Z; Zhang W
Aging (Albany NY); 2024 Feb; 16(3):2273-2298. PubMed ID: 38319706
[TBL] [Abstract][Full Text] [Related]
10. Glycolysis related lncRNA SNHG3 / miR-139-5p / PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance.
Yao Y; Chen X; Wang X; Li H; Zhu Y; Li X; Xiao Z; Zi T; Qin X; Zhao Y; Yang T; Wang L; Wu G; Fang X; Wu D
Int J Biol Macromol; 2024 Mar; 260(Pt 2):129635. PubMed ID: 38266860
[TBL] [Abstract][Full Text] [Related]
11.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
Yan Y; Mao X; Zhang Q; Ye Y; Dai Y; Bao M; Zeng Y; Huang R; Mo Z
Cancer Biomark; 2021; 31(1):87-96. PubMed ID: 33780364
[TBL] [Abstract][Full Text] [Related]
14. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
15. Predicting the prognosis, immune response, and immunotherapy in head and neck squamous cell carcinoma using a novel risk model based on anoikis-related lncRNAs.
Deng H; Wei Z; Du J; Shen Z; Zhou C
Eur J Med Res; 2023 Nov; 28(1):548. PubMed ID: 38017579
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a novel anoikis-related prognostic model for prostate cancer.
Zhang P; Lv W; Luan Y; Cai W; Min X; Feng Z
Mol Genet Genomic Med; 2024 Apr; 12(4):e2419. PubMed ID: 38572916
[TBL] [Abstract][Full Text] [Related]
17. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
18. Validation and identification of anoikis-related lncRNA signatures for improving prognosis in clear cell renal cell carcinoma.
Zhu Z; Wang Q; Zeng X; Zhu S; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3915-3933. PubMed ID: 38385949
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response.
Jiang Y; Ye Y; Huang Y; Wu Y; Wang G; Gui Z; Zhang M; Zhang M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15069-15083. PubMed ID: 37620430
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of Anoiki-Related Lncrna Signature Prediction Model for KIRC Prognosis.
Su Y; Yang J
Comb Chem High Throughput Screen; 2024 Jan; ():. PubMed ID: 38305400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
